poisar

Stocks · News reference

Summit Therapeutics and Lunit Announce Research Agreement for AI-Powered Tumor Microenvironment Analysis

Summit Therapeutics and Lunit have entered into a research agreement to utilize Lunit's AI-powered SCOPE IO platform to analyze the tumor microenvironment in support of Summit's ivonescimab immuno-oncology programs.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SMMT
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Not Specified

    Summit Expands Ashburn Data Center Capacity by 60% as Hyperscale Demand Squeezes Enterprise Colocation Market

    Summit announced a 60% capacity expansion at its Ashburn data center to address the shortage of colocation space for enterprises. The expansion comes as hyperscalers dominate the data center market, accounting for 59% of North American tenant demand, leaving traditional IT workloads struggling to secure capacity. The company's 'Colo in Any Market' program helps businesses find colocation options globally within 48 hours.

    SMMT